The Wall Street Journal saved patients from harm by revealing fraud at the heart of one of Silicon Valley's hottest companies. Were it not for the Journal's reporting in 2016, tens of thousands of patients would have been put at risk and a company built on fraudulent foundations would still be a Silicon Valley darling. Theranos, a $9 billion laboratory startup, had promised to revolutionize blood testing by drawing just a few drops of blood with a finger prick. It wasn't close. A team of Journal reporters, in a committed and extensive investigation, exposed how its technology didn't work, how the company tried to cover up its failures and how patients' lives were turned upside down and their health jeopardized.
Looks like you haven't made a choice yet.